Commentary: On the levels of patient selection in registry-based randomized controlled trials.
External validity
Generalizability
Patient selection
Pragmatic trials
Registry
Registry-based RCT
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
04 Feb 2019
04 Feb 2019
Historique:
received:
30
04
2018
accepted:
18
01
2019
entrez:
6
2
2019
pubmed:
6
2
2019
medline:
14
6
2019
Statut:
epublish
Résumé
Registry-based randomized controlled trials (RCTs) are presumed to include a less-selected patient population and thus to have enhanced generalizability compared to conventional RCTs. However, this view disregards the levels of patient selection in registry-based RCTs: the registry selection level and the trial selection level. At both levels, systematic selection can occur and generalizability can be diminished. Nevertheless, using a registry as a basis for recruitment, randomization, and data collection results in an advantage: the trial selection takes place within the registry framework, where baseline characteristics of non-enrolled patients are automatically documented as well. By comparing the baseline variables of the enrolled and non-enrolled patients, the trial selection can always be investigated, which gives a sound basis for discussing the generalizability to the registry population.
Identifiants
pubmed: 30717778
doi: 10.1186/s13063-019-3214-x
pii: 10.1186/s13063-019-3214-x
pmc: PMC6360703
doi:
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
100Références
J Clin Psychopharmacol. 2000 Dec;20(6):699-702
pubmed: 11106145
Lancet. 2005 Jan 1-7;365(9453):82-93
pubmed: 15639683
PLoS Clin Trials. 2006 May;1(1):e9
pubmed: 16871331
JAMA. 2008 Jan 30;299(4):409-16
pubmed: 18230778
Int J Epidemiol. 2010 Feb;39(1):89-94
pubmed: 19376882
Basic Clin Pharmacol Toxicol. 2010 Feb;106(2):86-94
pubmed: 19961477
Lancet. 2010 Mar 27;375(9720):1090-9
pubmed: 20231034
Heart. 2010 Oct;96(20):1617-21
pubmed: 20801780
Am Heart J. 2010 Dec;160(6):1042-8
pubmed: 21146656
Circulation. 2011 Aug 2;124(5):544-54
pubmed: 21709065
J Am Coll Cardiol. 2011 Aug 23;58(9):915-22
pubmed: 21851879
Circulation. 2012 Mar 13;125(10):1246-55
pubmed: 22308301
Lancet. 2013 Feb 23;381(9867):661-9
pubmed: 23374649
N Engl J Med. 2013 Oct 24;369(17):1587-97
pubmed: 23991656
N Engl J Med. 2013 Oct 24;369(17):1579-81
pubmed: 23991657
Lancet Oncol. 2013 Oct;14(11):1077-1085
pubmed: 24028813
N Engl J Med. 2014 Sep 18;371(12):1111-20
pubmed: 25176395
Circulation. 2015 Jan 6;131(1):34-42
pubmed: 25406305
Lancet. 2015 Apr 18;385(9977):1527-35
pubmed: 25601789
Nat Rev Cardiol. 2015 May;12(5):312-6
pubmed: 25781411
Eur Heart J. 2016 Jan 1;37(1):67-119
pubmed: 26320113
J Clin Epidemiol. 2016 Dec;80:16-24
pubmed: 27555082
Curr Heart Fail Rep. 2017 Apr;14(2):59-70
pubmed: 28247180
Trials. 2017 Apr 5;18(1):163
pubmed: 28381291
J Clin Epidemiol. 2018 Jan;93:120-127
pubmed: 28951111
J Clin Psychopharmacol. 1996 Apr;16(2):170-6
pubmed: 8690832